Compare AUBN & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AUBN | ECOR |
|---|---|---|
| Founded | 1907 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.8M | 81.0M |
| IPO Year | 1996 | 2018 |
| Metric | AUBN | ECOR |
|---|---|---|
| Price | $26.18 | $6.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 1.3K | ★ 73.0K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.61% | N/A |
| EPS Growth | ★ 13.66 | N/A |
| EPS | ★ 0.63 | N/A |
| Revenue | $619,000.00 | ★ $32,032,000.00 |
| Revenue This Year | N/A | $33.60 |
| Revenue Next Year | N/A | $30.40 |
| P/E Ratio | $41.67 | ★ N/A |
| Revenue Growth | 0.81 | ★ 27.20 |
| 52 Week Low | $21.60 | $4.16 |
| 52 Week High | $28.88 | $10.50 |
| Indicator | AUBN | ECOR |
|---|---|---|
| Relative Strength Index (RSI) | 49.79 | 38.78 |
| Support Level | $24.09 | $5.56 |
| Resistance Level | $26.79 | $7.12 |
| Average True Range (ATR) | 0.41 | 0.51 |
| MACD | -0.10 | 0.05 |
| Stochastic Oscillator | 16.67 | 28.91 |
Auburn National Bancorp Inc is a bank holding company registered with the Board of Governors of the Federal Reserve System (the Federal Reserve). As a bank holding company, the Company may diversify into a broader range of financial services and other business activities than are currently permitted to the Bank under applicable laws and regulations. The holding company structure also provides greater financial and operating flexibility than is presently permitted to the Bank. The Company's business is conducted through the Bank and its subsidiaries. Although it has no immediate plansto conduct any other business, the Company may engage directly or indirectly in several activities closely related to banking permitted by the Federal Reserve.
electroCore Inc is a bioelectronic technology company whose mission is to improve health and quality of life through non-invasive bioelectronic technologies. Its two commercial products are gammaCore non-invasive vagus nerve stimulation, or nVNS, and Quell Fibromyalgia, or Quell. It also sells Truvaga and TAC-STIM products, which are handheld, personal-use consumer products developed to promote general wellness and human performance. It operates in one segment: Bioelectronic Innovations. Geographically, it operates in the United States, the United Kingdom, Japan, and Other.